NCT06937281View on ClinicalTrials.gov

SABR PRIMER - Evaluating Stereotactic Ablative Radiotherapy for Primary and Regional Breast Tumors

NANot yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 1, 2025

Primary Completion Date

June 30, 2029

Study Completion Date

July 30, 2030

Conditions
Breast CancerMetastases
Interventions
RADIATION

SABR

Prescription dose/fractionation: 26Gy/5 with 40Gy/5 +/- 35Gy/5 Boost Radiation Technique: VMAT Treatment Frequency: Every other day (EOD)

Trial Locations (1)

V5Z 4E6

BC Cancer - Vancouver, Vancouver

All Listed Sponsors
lead

British Columbia Cancer Agency

OTHER